|
Administration
Adefovir: May be taken with or without food.
|
|
Contraindications
Hypersensitivity. Lactation.
|
|
Special Precautions
Patient with hepatomegaly or other risk factors for liver disease. Renal impairment. Children and elderly. Monitoring Parameters Monitor LFTs and renal function before treatment and then every 3 months. Perform HBV DNA test every 3 months until detectable then every 3-6 months thereafter. Monitor for lactic acidosis and hepatic status regularly during treatment. Closely monitor hepatic function several months following discontinuation of therapy. Determine HIV status prior to treatment.
|
|
Adverse Reactions
Significant: Nephrotoxicity (chronic and long-term use), exacerbation of hepatitis, HIV resistance (when used to treat chronic hepatitis B co-infected with undiagnosed or untreated HIV infection).
Gastrointestinal disorders: Nausea, abdominal pain, flatulence, dyspepsia, vomiting, diarrhoea, pancreatitis.
General disorders and administration site conditions: Asthenia.
Investigations: Increased serum creatinine.
Metabolism and nutrition disorders: Hypophosphataemia.
Musculoskeletal and connective tissue disorders: Myopathy, osteomalacia (manifested as bone pain and fracture).
Nervous system disorders: Headache.
Renal and urinary disorders: Fanconi syndrome, proximal renal tubulopathy, renal failure.
Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis. |
|
Drug Interactions
Increased nephrotoxicity with other nephrotoxic agents (e.g. aminoglycosides, cyclosporine, tacrolimus, vancomycin, certain NSAIDs). Increase serum concentration with other drugs eliminated by renal excretion. May decrease the therapeutic effect of tenofovir.
|
|
CIMS Class
|
Sign Out
